Kidney Inflammation Warning For PPI Omeprazole In Europe
Executive Summary
Cases of acute tubulointerstitial nephritis linked to omeprazole use flagged to the EMA leads to new product information warnings related to a possible risk of kidney inflammation for drugs containing the PPI sold in the EU.
You may also be interested in...
SCARs Label Warning For OTC PPIs In US Starts With Perrigo’s 131 Omeprazole Product Options
FDA approves warning for severe cutaneous adverse reactions on labeling for Perrigo's 131 20-mg omeprazole delayed-release tablet products across unflavored and cool mint or wild berry-mint options and 14-, 28- and 42-count packages.
Rare Skin Allergy Warning Spreads To Nexium 24HR
FDA approves request after Nexium 24HR marketer Haleon responded March to changes-being-effected letter asking for label change to the delayed-release PPI.
People On The Move: Appointments At Orkla, PAGB, Afepadi
A round-up of the latest appointments in Europe's consumer health industry: Orkla Health names BioGaia's Ducellier as its CEO; PAGB makes changes to its board; and Afepadi names Uriach's Gispert as its president.